0000899243-20-030412.txt : 20201104 0000899243-20-030412.hdr.sgml : 20201104 20201104200013 ACCESSION NUMBER: 0000899243-20-030412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201102 FILED AS OF DATE: 20201104 DATE AS OF CHANGE: 20201104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schambye Hans T. CENTRAL INDEX KEY: 0001825776 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39655 FILM NUMBER: 201288225 MAIL ADDRESS: STREET 1: C/O GALECTO, INC. STREET 2: OLE MAALOES VEJ 3 CITY: COPENHAGEN N STATE: G7 ZIP: DK-2200 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Galecto, Inc. CENTRAL INDEX KEY: 0001800315 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 371957007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: GALECTO BIOTECH AB STREET 2: OLE MAALOES VEJ3 CITY: COPENHAGEN STATE: G7 ZIP: DK-2200 BUSINESS PHONE: 45-70-70-52-10 MAIL ADDRESS: STREET 1: GALECTO BIOTECH AB STREET 2: OLE MAALOES VEJ3 CITY: COPENHAGEN STATE: G7 ZIP: DK-2200 FORMER COMPANY: FORMER CONFORMED NAME: Galecto Inc. DATE OF NAME CHANGE: 20200116 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-02 0 0001800315 Galecto, Inc. GLTO 0001825776 Schambye Hans T. C/O GALECTO, INC. OLE MAALOES VEJ 3 COPENHAGEN N G7 DK-2200 DENMARK 1 1 0 0 Chief Executive Officer Common Stock 2020-11-02 4 C 0 13931 A 39928 D Stock Option (right to buy) 1.95 2020-06-24 4 A 0 207976 0.00 A 2030-06-24 Common Stock 207976 207976 D Stock Option (right to buy) 7.70 2020-10-07 4 A 0 519940 0.00 A 2030-10-06 Common Stock 519940 519940 D Series C-1 Preferred Stock 2020-11-02 4 C 0 5359 0.00 D Common Stock 13931 0 D The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. 25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. /s/ Jonathan Freve, attorney-in-fact 2020-11-04